Skip to main content

Advertisement

Table 3 Overview of the included studies

From: A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks—results from the Lassa fever pilot

Domain No. of extracted studies Setting* No. of participants Populations Study objectives Intervention
Clinical phenotype and natural history of disease 25 14 Nigeria 7 Sierra Leone 3 Liberia 3 Mali 1 USA Total: n = 6680 LF pos. n = 1734 Adults Pregnant women Children, Infants, Neonates (0 to > 65 years old) Clinical presentation, symptoms (n = 15) LF fatality rate (n = 11) Biochemical laboratory parameters (n = 7) N/A
Transmission and prevention 12 5 Sierra Leone 4 Nigeria 1 Germany 1 Liberia 1 UK 1 USA Total: n = 1980 LF pos: n = 281 Adults Pregnant women Children, Infants, Neonates (0 to 73 years) Ribavirin as PEP (n = 4) Risk of nosocomial transmission (n = 5) Ribavirin
Diagnostics 7 4 Sierra Leone 2 Liberia 1 Nigeria Total: n = 3338 LF pos: n = 897 Adults Children PCR for diagnostics (n = 3) PCR and hybridization (n = 1) LFI, ELISA and PCR (n = 1) IgM as early marker (n = 1) PCR, LFI, ELISA, virus isolation
Immune response 5 2 Guinea 2 Sierra Leone 1 Liberia 1 Mali Total: n = 4570 LF pos: n = 1437 Adults Children, Infants (7 months to 83 years) Levels of inflammatory cytokines chemokines and other pro-inflammatory mediators (n = 1) Prevalence of LASV-specific IgG antibodies (LV IgG) (n = 1) Population LF seroconversion (n = 1)  
Drug therapy and supportive care 10 4 Nigeria 4 Sierra Leone 2 USA 1 Germany Total: n = 1516 LF pos: n = 792 Adults Pregnant women Children, Infants, Neonates (0 to 65 years) Therapeutic effectiveness of Ribavirin (n = 9) Therapeutic effectiveness of LF convalescent plasma therapy (n = 2) Ribavirin treatment adverse event (n = 1) Ribavirin iv. Ribavirin oral Convalescent plasma
Risk factors for more severe disease 4 3 Sierra Leone 2 Guinea Total: n = 2110 LF pos. or probable: n = 562 Adults Pregnant women Children, Infants, Neonates (0 to > 60 years) Correlation of cytokine levels and outcome (n = 2) Correlation of AST and outcomes (n = 1) Correlation of BUN, ALP, ALT, and outcomes (n = 1) Correlation of viremia level and outcome (n = 1) Risk factors for positive LASV IgG (n = 1)  
  1. Abbreviations: LF Lassa fever, LASV Lassa virus, Pos positive, PEP post-exposure prophylaxis, PCR polymerase chain reaction, LFI lateral flow immunoassay, ELISA enzyme-linked immunosorbent assay, Ig immunoglobulin, AST aspartate aminotransferase, BUN blood urea nitrogen, ALP alkaline phosphatase, ALT alanine aminotransferase
  2. *Some studies were set in more than one country